Keros Therapeutics adjusts TROPOS trial of cibotercept amid safety concerns
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced significant changes to its Phase 2 TROPOS trial evaluating cibotercept safety concerns in patients with pulmonary ... Read More
Tentative approval granted to Alembic Pharmaceuticals for pulmonary hypertension treatment by FDA
Alembic Pharmaceuticals Limited has achieved a significant milestone by securing tentative approval from the US Food & Drug Administration (USFDA) for its Selexipag for Injection, ... Read More